U-CYT

Q:CYT - CYTEIR THERAPEUTICS INC - http://cytec.com/

14:57:07 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
CYT - Q	DEFUNCT					3.02							3.19 1.48	Mar 15	Mar 07	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - All 0 today

More trades...

Time ET	Ex	Price	Change	Volume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-03-07 16:30	U:CYT	News Release200	Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
2023-10-12 07:30	U:CYT	News Release200	Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
2023-06-30 08:00	U:CYT	News Release200	Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
2023-06-03 09:00	U:CYT	News Release200	Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
2023-05-10 16:01	U:CYT	News Release200	Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

Date ET

Symbol

Type

Headline

2024-03-07 16:30

U:CYT

News Release

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

2023-10-12 07:30

U:CYT

News Release

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile